No Picture
News

BridGene Biosciences Announces Titles and Authors of Five Abstracts Accepted for Poster Presentations at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

SAN JOSE, Calif.: SAN JOSE, Calif., Sept. 30, 2021 /PRNewswire/ — BridGene Biosciences, Inc., a biotechnology company using a unique chemoproteomic technology to discover and develop small molecules for high value, traditionally undruggable targets, a… […]

No Picture
News

Curebase Solutions Supports Another InBios FDA Emergency Use Authorization for COVID-19 IgG Antibody Rapid Test

SAN FRANCISCO: SAN FRANCISCO, Sept. 30, 2021 /PRNewswire/ — Curebase, a company committed to democratizing access to clinical studies, teamed up again this summer with InBios International Inc., a leading developer of diagnostic tests for emerging inf… […]

No Picture
News

Perfect Day Raises $350 Million to Expand Consumer and Enterprise Biology Platforms

BERKELEY, Calif.: BERKELEY, Calif., Sept. 30, 2021 /PRNewswire/ — Today, Perfect Day, Inc., best known as the creator of the world’s first animal-free milk protein, announced a $350 million Series D funding round intended to fuel the company’s expande… […]

No Picture
News

Sutro Biopharma Announces Extension of Cytokine Derivative Research Program Under Collaboration with Merck

SOUTH SAN FRANCISCO, Calif.: SOUTH SAN FRANCISCO, Calif., Sept. 30, 2021 /PRNewswire/ — Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineer… […]

No Picture
News

4D Molecular Therapeutics to Participate in Chardan’s 5th Annual Genetic Medicines Conference

EMERYVILLE, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in… […]

No Picture
News

Denali Therapeutics Announces Upcoming Presentations on EIF2B Activator DNL343 and RIPK1 Inhibitor SAR443820/DNL788 at the 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerat… […]